跳至主要内容
临床试验/TCTR20230713001
TCTR20230713001已完成3 期

Efficacy of Lower Dose of Dexamethasone Premedication in Patient Receiving Docetaxel-Based Chemotherapy in Preventing Hypersensitivity Reaction: A Randomized Controlled Trial

Chulalongkorn university0 个研究点目标入组 46 人开始时间: 2023年7月13日最近更新:
适应症

试验速览

阶段
3 期
状态
已完成
入组人数
46

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional

入排标准

年龄范围
18 Years 至 N/A (No limit)(—)
性别
All

入选标准

  • Patient receiving single agent Docetaxel tri-weekly regimen.
  • Patient has never received Docetaxel.
  • Eastern Cooperative Oncology Group (ECOG) performance status 0 to 2.
  • Age 18 or older.

排除标准

  • Prostate cancer patient receiving Docetaxel with prednisolone for treatment.
  • Patient on steroid within 14 days prior to randomization.
  • Patient on immunosuppressive drug within 30 days prior to randomization.
  • Patient with severe allergic reaction such as, anaphylaxis, severe cutaneous adverse drug reaction (Stevens-Johnson syndrome/toxic epidermal necrolysis (SJS/TEN), drug reaction with eosinophilia and systemic symptoms (DRESS), acute generalized exanthematous pustulosis (AGEP)).
  • Patient with history of hypersensitivity reaction grade 3 or higher to taxane based chemotherapy.
  • Patient with underlying disease diabetes mellitus.

研究者

相似试验